ArticleClinical and experimental medicine2026
Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies.
Article in Clinical and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Although many predictive models for metabolic dysfunction-associated steatotic liver disease (MASLD) have been developed, their performance remains suboptimal. We aimed to develop an interpretable machine learning (ML)-based plasma biomarker model for identifying prevalent MASLD. Data from the National Health and Nutrition Examination Survey (NHANES 2017-2020) were randomly divided into a training cohort (N = 2760) and an internal cohort (N = 1184). Eleven ML algorithms were employed to construct classification models. Model interpretability was visualized via the SHapley Additive exPlanations (SHAP) method. External validation of these models was further conducted using data from the Korea NHANES (KNHANES) 2019-2021. The association between the selected features and prevalent MASLD was evaluated using restricted cubic spline regression analysis. Feature selection was performed using LASSO regression and the Boruta algorithm. Key predictors included diabetes mellitus (DM), waist circumference (WC), age, hypertension, and atherogenic index of plasma (AIP). All evaluated ML algorithms demonstrated robust predictive capabilities, with areas under the curve (AUC) exceeding 0.70. Among these, the Extra Trees (ET) performed the best, achieving an AUC of 0.879 (95% CI 0.856-0.897) in the internal testing group and maintaining good performance in the external KNHANES cohort with an AUC of 0.822 (95% CI 0.815-0.829). The DeLong test revealed significant differences in AUC between ET and other algorithms. These findings suggest that age, WC, DM, hypertension, and AIP are informative features associated with prevalent MASLD. The ET model showed strong discriminative performance and may serve as a practical tool for MASLD screening.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.